Background: Recent studies have suggested that men with elevated plasma levels of insulin-like growth factor-I (IGF-I) may have an increased risk of prostate cancer. Furthermore, IGF-binding proteins (IGFBPs) and insulin can modulate the activity of IGF-I, In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer. Methods: We conducted a nested case-control study within the Northern Sweden Health and Disease Cohort Study. We measured levels of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and insulin in plasma samples from 149 men who had a diagnosis of prostate cancer between I month and 10 Sears after blood collection and among 298 control men. All statistical tests are two-sided. Results: Case subjects had statistically significantly higher mean levels of IGF-I than control subjects (229 ng/mL; 95% confidence interval [CT] = 218-240 ng/mL] versus 214 ng/mL [95% CI = 208-221 ng/mL]; P = .02) and IGFBP-3 (2611 ng/mL [95% CI = 2518-2704 ng/mL] versus 2498 ng/mL [95% CI = 2437-2560 ng/mL]; P = .04). Conditional logistic regression analyses showed increases in prostate cancer risk with rising levels of IGF-I (P-for trend = .02) and IGFBP-3 (P-for trend = .03). In case subjects younger than 59 years at the time of blood collection, the risk associated with increased IGF-I was higher (P-for trend = .01), whereas the risk associated with increased IGFBP-3 was lower (P-for trend = .44) than the corresponding risks in the full cohort. Prostate cancer risk was not associated with levels of IGFBP-1, IGFBP-2, or insulin. Conclusions: Prostate cancer risk is increased in men with elevated plasma IGF-I, This association was particularly strong in younger men in this study, suggesting that circulating IGF-I mag be specifically involved in the early pathogenesis of prostate cancer.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study

Riboli E;
2000-01-01

Abstract

Background: Recent studies have suggested that men with elevated plasma levels of insulin-like growth factor-I (IGF-I) may have an increased risk of prostate cancer. Furthermore, IGF-binding proteins (IGFBPs) and insulin can modulate the activity of IGF-I, In this study, we sought to determine the role of IGF-I as well as IGFBPs-1, -2, and -3 and insulin as possible etiologic factors for prostate cancer. Methods: We conducted a nested case-control study within the Northern Sweden Health and Disease Cohort Study. We measured levels of IGF-I, IGFBP-1, IGFBP-2, IGFBP-3, and insulin in plasma samples from 149 men who had a diagnosis of prostate cancer between I month and 10 Sears after blood collection and among 298 control men. All statistical tests are two-sided. Results: Case subjects had statistically significantly higher mean levels of IGF-I than control subjects (229 ng/mL; 95% confidence interval [CT] = 218-240 ng/mL] versus 214 ng/mL [95% CI = 208-221 ng/mL]; P = .02) and IGFBP-3 (2611 ng/mL [95% CI = 2518-2704 ng/mL] versus 2498 ng/mL [95% CI = 2437-2560 ng/mL]; P = .04). Conditional logistic regression analyses showed increases in prostate cancer risk with rising levels of IGF-I (P-for trend = .02) and IGFBP-3 (P-for trend = .03). In case subjects younger than 59 years at the time of blood collection, the risk associated with increased IGF-I was higher (P-for trend = .01), whereas the risk associated with increased IGFBP-3 was lower (P-for trend = .44) than the corresponding risks in the full cohort. Prostate cancer risk was not associated with levels of IGFBP-1, IGFBP-2, or insulin. Conclusions: Prostate cancer risk is increased in men with elevated plasma IGF-I, This association was particularly strong in younger men in this study, suggesting that circulating IGF-I mag be specifically involved in the early pathogenesis of prostate cancer.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11699/9709
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 317
social impact